Melody.education: Educational programs on Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD)

Explore the alarming rise of Nonalcoholic Steatohepatitis (NASH) and its connection to global health issues like obesity and diabetes. Delve into the significance of liver fibrosis and its role in the disease’s progression. The emerging role of the hepatic thyroid hormone pathway in understanding NASH's pathology is also highlighted. This discussion sheds light on therapeutic needs and potential advancements in managing this prevalent condition.

In this engaging discussion, Professor Jörn Schattenberg shares his groundbreaking research on the hepatic thyroid hormone pathway's impact on Nonalcoholic Steatohepatitis (NASH). He highlights the alarming increase in NASH cases and its significant mortality risks. The conversation delves into advancements in diagnosis and management strategies, including promising non-invasive testing methods. Schattenberg emphasizes the urgent need for innovative therapeutic solutions to address this growing health crisis and improve patient outcomes.

Part 3: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: The Underestimated Importance of Thyroid Hormone Pathway in the Pathophysiology of NASH with Prof Meena Bansal, MD

Delve into the intriguing connection between hepatic hypothyroidism and Nonalcoholic Steatohepatitis (NASH). The discussion highlights the increasing prevalence of these conditions, alongside promising liver-targeted treatments in clinical trials. Expect insights into how thyroid hormones could reshape understanding and management of fatty liver diseases. A captivating exploration of emerging medical pathways awaits!

Scott Isaacs, a clinical endocrinologist specializing in NASH, shares valuable insights alongside Barton Isaac, a PharmD. They delve into the management of Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease within endocrinology. Key discussions include the importance of non-invasive tests like the FIB4 score for risk stratification and identifying high-risk patients, particularly those with diabetes. They emphasize the need for better education among healthcare providers to effectively address these interconnected metabolic issues.

Dive into the world of Nonalcoholic Steatohepatitis, a severe form of liver disease. The discussion highlights its definitions, epidemiology, and underlying mechanisms. Insights from healthcare providers shed light on patient risk factors and management strategies. Discover why understanding NASH is crucial for tackling this progressive condition. It's an enlightening journey into liver health you won't want to miss!

Christina Hanson, an expert in Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD), shares her insights on these pressing health issues. She discusses the alarming rise in NAFLD cases linked to obesity and diabetes. Hanson breaks down the differences between NAFLD and its progressive form, NASH, emphasizing the importance of understanding disease progression and epidemiology. She also highlights how fibrosis affects patient outcomes, making this a crucial topic for anyone interested in liver health.

Ann Moore, FNP-C, a nurse practitioner specializing in liver disease, offers an insightful overview of Nonalcoholic Steatohepatitis (NASH). She discusses the importance of identifying at-risk patients, emphasizing the links to metabolic disorders. Listeners learn about screening tools and non-invasive testing methods. Moore highlights lifestyle changes essential for managing the disease and stresses the need for proactive engagement with patients to combat NASH effectively.